4.5 Article

RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol

Journal

VACCINE
Volume 25, Issue 42, Pages 7459-7469

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.08.018

Keywords

vaccine; ricin; bioterrorism; RiVax

Funding

  1. NIAID NIH HHS [U01 AI056372-01, AI-056372, U01 AI056372-04, U01 AI056372-02, U01 AI056372-03, U01 AI056372] Funding Source: Medline

Ask authors/readers for more resources

Ricin is a plant toxin that is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax), which contains mutations in both known toxic sites, has no residual toxicity at doses at least 800 times the immunogenic dose. RiVax without adjuvant given intramuscularly (i.m.) protected mice against intraperitoneally administered ricin. Furthermore the vaccine without alum was safe and immunogenic in human volunteers. Here we describe the development of gavage and aerosol ricin challenge models in mice and demonstrate that i.m. vaccination protects mice against ricin delivered by either route. Also RiVax protects against aerosol-induced lung damage as determined by histology and lung function tests. (c) 2007 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available